These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38179880)
41. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. Burgel PR Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423591 [No Abstract] [Full Text] [Related]
42. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis. McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711 [No Abstract] [Full Text] [Related]
43. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202 [TBL] [Abstract][Full Text] [Related]
45. Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Advanced Cystic Fibrosis Lung Disease. Djavid AR; Thompson AE; Irace AL; Gusman E; Altman K; DiMango EA; Keating CL Ann Am Thorac Soc; 2021 Nov; 18(11):1924-1927. PubMed ID: 34000224 [No Abstract] [Full Text] [Related]
46. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. Shaughnessy CA; Zeitlin PL; Bratcher PE J Cyst Fibros; 2022 Jul; 21(4):637-643. PubMed ID: 35248469 [TBL] [Abstract][Full Text] [Related]
47. Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals. Almulhem M; Harnett N; Graham S; Haq I; Visram S; Ward C; Brodlie M BMJ Open Respir Res; 2022 Oct; 9(1):. PubMed ID: 36207030 [TBL] [Abstract][Full Text] [Related]
48. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis. Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662 [No Abstract] [Full Text] [Related]
49. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease. O'Shea KM; O'Carroll OM; Carroll C; Grogan B; Connolly A; O'Shaughnessy L; Nicholson TT; Gallagher CG; McKone EF Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33154033 [No Abstract] [Full Text] [Related]
50. Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor. Meltzer LJ; Gross JE J Cyst Fibros; 2024 Jan; 23(1):132-136. PubMed ID: 37210228 [No Abstract] [Full Text] [Related]
51. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis. Middleton PG; Taylor-Cousar JL Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928 [No Abstract] [Full Text] [Related]
52. Nontuberculous mycobacterial pulmonary infections in the era of elexacaftor-tezacaftor-ivacaftor. Mingora CM; Caverly LJ J Cyst Fibros; 2024 Jan; 23(1):3-4. PubMed ID: 38307802 [No Abstract] [Full Text] [Related]
53. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314 [No Abstract] [Full Text] [Related]
54. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor. Becq F; Mirval S; Carrez T; Lévêque M; Billet A; Coraux C; Sage E; Cantereau A Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34266939 [TBL] [Abstract][Full Text] [Related]
55. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19. Hong E; Almond LM; Chung PS; Rao AP; Beringer PM Clin Pharmacol Ther; 2022 Jun; 111(6):1324-1333. PubMed ID: 35292968 [TBL] [Abstract][Full Text] [Related]
56. Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study. Salvatore D; Cimino G; Troiani P; Bignamini E; Esposito I; Leonetti G; Zanda M; Manunza D; Pepe A Pediatr Pulmonol; 2022 Sep; 57(9):2253-2256. PubMed ID: 35577767 [No Abstract] [Full Text] [Related]
57. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849 [No Abstract] [Full Text] [Related]
58. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum. Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357 [TBL] [Abstract][Full Text] [Related]
59. Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis. Martin I; McDonald N; Wilson D; Ratjen F; Grasemann H J Cyst Fibros; 2024 Jan; 23(1):109-111. PubMed ID: 37867075 [No Abstract] [Full Text] [Related]
60. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series. Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]